Mangoceuticals (MGRX) Liabilities and Shareholders Equity (2022 - 2026)

Mangoceuticals has disclosed Liabilities and Shareholders Equity across 5 years of filings, most recently posting $14.4 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $14.4 million, down 33.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.9 million (up 1.13% YoY), and the FY2025 annual result was $16.1 million, up 4.68% from the prior year.
• Liabilities and Shareholders Equity came in at $14.4 million for Q1 2026 at Mangoceuticals, down from $16.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $21.8 million in Q1 2025 to a low of $301447.0 in Q1 2024.
• The 5-year median for Liabilities and Shareholders Equity is $14.6 million (2024), against an average of $10.5 million.
• Across the five-year window, Liabilities and Shareholders Equity sank 92.67% in 2024 and jumped 7116.48% in 2025, its largest moves.
• Mangoceuticals' Liabilities and Shareholders Equity stood at $1.0 million in 2022, then climbed by 4.74% to $1.1 million in 2023, then soared by 1362.75% to $15.4 million in 2024, then advanced by 4.68% to $16.1 million in 2025, then slipped by 10.2% to $14.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $14.4 million (Q1 2026), $16.1 million (Q4 2025), and $16.5 million (Q3 2025), per Business Quant data.